•  
  •  
  •  
  •  

2026-07-20 14:56:07

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • D. P. Abhushan Reports Strong Q1 FY27 Performance: Net Profit Surges 77% YoY to ₹64.45 Crore
  • Regency Fincorp Reports Outstanding Q1 FY27 Results: Net Profit Surges 98.9% Sequentially to ₹7.03 Crore
  • Vimta Labs Reports Strong Q1 FY27 Results: Net Profit Rises 11.4% YoY to ₹21.04 Crore
  • Grand Foundry Limited Reports Strong Turnaround in Q1 FY27: Net Profit Soars to ₹2.11 Crore
  • Mahindra Logistics Reports Robust Turnaround in Q1 FY27: Net Profit Reaches ₹27.83 Crore as Revenue Crosses ₹2,000 Crore

Keywords Selected:  IndocoRemedies

Research

  • Indoco Remedies - Q4FY22 Result Update - In-line quarter; strong revenue guidance for US & EU mkt - Upgrade to 'BUY'

Stock Report

  • Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit
  • Indoco's formulation plant at Baddi - Plant III receives EU GMP certification
  • Indoco Remedies Ltd recommends dividend of Rs. 0.20
  • Indoco Remedies Ltd Q4 FY26 consolidated loss at Rs. 21.64 crores
  • Indoco Remedies' testing facility completes US FDA PAI
  • Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
  • Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
  • USFDA successfully completes inspection at Indoco's API manufacturing facility at Patalganga with zero observations
  • Indoco receives Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II
  • Indoco Remedies Ltd Q1 FY2026 consolidated loss at Rs. 35.79 crores
  • Indoco Remedies Ltd announces the first day launch of Ticagrelor filmcoated tablets through its subsidiary in the United Kingdom
  • Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP 200 mg
  • Indoco's Clinical Research Organisation - AnaCipher completes US FDA inspection
  • Indoco Remedies Ltd consolidated Q3FY25 loss widens to Rs. 26.39 crores
  • Indoco Remedies Limited receives warning letter from USFDA for Goa plants
  • Indoco announces strategic distribution partnership with Clarity Pharma, UK
  • Indoco Remedies Ltd Q2FY25 consolidated loss at Rs. 9.57 crores
  • Indoco Remedies Ltd receives OAI status from USFDA for Goa Plant 2 & 3
  • Indoco Remedies receives final ANDA approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg OTC
  • Indoco Remedies receives USFDA final ANDA approval for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation
  • Indoco Remedies Ltd gets 7 observations from USFDA for Plant 2 and 3 at Goa
  • Indoco Remedies Ltd Q1 FY25 consolidated PAT slumps to Rs. 2.62 crores
  • Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
  • Warren Remedies Pvt Ltd commences commercial production of Pharmaceutical Intermediates

Latest Post

  • D. P. Abhushan Reports Strong Q1 FY27 Performance: Net Profit Surges 77% YoY to ₹64.45 Crore
  • Regency Fincorp Reports Outstanding Q1 FY27 Results: Net Profit Surges 98.9% Sequentially to ₹7.03 Crore
  • Vimta Labs Reports Strong Q1 FY27 Results: Net Profit Rises 11.4% YoY to ₹21.04 Crore
  • Grand Foundry Limited Reports Strong Turnaround in Q1 FY27: Net Profit Soars to ₹2.11 Crore
  • Mahindra Logistics Reports Robust Turnaround in Q1 FY27: Net Profit Reaches ₹27.83 Crore as Revenue Crosses ₹2,000 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025